Exelixis
EXEL
$56.13
Share price
2.47%
Change (1 day)
62.07%
Change (1 year)
Categories
Exelixis, Inc. is an American genomics-based drug discovery company and the producer of Cometriq, a treatment for medullary thyroid cancer.
Revenue for Exelixis (EXEL)
Revenue in 2024 (TTM): A$3.29 Billion
According to Exelixis's latest financial reports the company's current revenue (TTM 
) is A$3.44 Billion. an increase over the revenue in the year 2023 that were of A$2.68 Billion. The revenue is the total amount of income that a company generates by the sale of goods or services. Unlike with the earnings no expenses are subtracted.
Revenue history for Exelixis from 2000 to 2024
Annual revenue
| Year | Revenue | Change |
|---|---|---|
| 2024 | A$3.48 B | 29.79% |
| 2023 | A$2.68 B | 13.47% |
| 2022 | A$2.36 B | 19.61% |
| 2021 | A$1.97 B | 54.12% |
| 2020 | A$1.28 B | -7.09% |
| 2019 | A$1.38 B | 14.05% |
| 2018 | A$1.21 B | 109.12% |
| 2017 | A$0.57 B | 118.21% |
| 2016 | A$0.26 B | 420.53% |
| 2015 | A$51.02 M | 66.3% |
| 2014 | A$30.68 M | -12.67% |
| 2013 | A$35.13 M | -23.06% |
| 2012 | A$45.66 M | -83.84% |
| 2011 | A$0.28 B | 55.06% |
| 2010 | A$0.18 B | 7.83% |
| 2009 | A$0.16 B | 1.13% |
| 2008 | A$0.16 B | 28.71% |
| 2007 | A$0.12 B | 3.69% |
| 2006 | A$0.12 B | 20.57% |
| 2005 | A$0.10 B | 51.99% |
| 2004 | A$68.3 M | -1.49% |
| 2003 | A$69.33 M | -11.86% |
| 2002 | A$78.66 M | -2.09% |
| 2001 | A$80.34 M | 81.44% |
| 2000 | A$44.28 M |
Revenue for similar companies or competitors
| Company | Revenue | Revenue differencediff. | Country |
|---|---|---|---|
 | A$63.86 B | 1,752.75% | 🇬🇧 UK |
 | A$76.23 B | 2,111.48% | 🇫🇷 France |
 | A$101.99 B | 2,858.82% | 🇺🇸 USA |
 | A$76.77 B | 2,127.14% | 🇺🇸 USA |
 | A$53.12 B | 1,441.20% | 🇺🇸 USA |
 | A$141.18 B | 3,995.59% | 🇺🇸 USA |
 | A$101.13 B | 2,833.83% | 🇺🇸 USA |
 | A$17.33 M | -99.50% | 🇺🇸 USA |
 | A$0.14 B | -95.65% | 🇺🇸 USA |